Overview

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Status:
Not yet recruiting
Trial end date:
2039-10-20
Target enrollment:
Participant gender:
Summary
This study is a single-armed, open-label,multicenter Phase 1/2 study to evaluate the safety and efficacy of CT120 in subjects with relapsed/refractory B-cell non-Hodgkin's lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Nanjing IASO Biotherapeutics Co.,Ltd